Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
:MYGN
MYGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.76 - $29.30
Previous CloseN/A
Volume154.82K
Average Volume (3M)1.30M
Market Cap
$356.73M
Enterprise Value$571.38M
Total Cash (Recent Filing)$91.80M
Total Debt (Recent Filing)$157.60M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 04, 2025EPS Estimate
>-0.01Last Dividend Ex-Date
Jul 01, 2009Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding92,177,380
10 Day Avg. Volume1,515,184
30 Day Avg. Volume1,296,324
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.60
Enterprise Value/Revenue0.69
Enterprise Value/Gross Profit0.98
Enterprise Value/Ebitda-9.34
Forecast
1Y Price Target
$6.40Price Target Upside65.37% Upside
Rating ConsensusHold
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMYGN reported a positive 2Q after a weak 1Q, with sales 5% ahead of consensus.
Innovation And Product DevelopmentA partnership with PATHOMIQ has been launched to advance AI-powered testing solutions, which is expected to accelerate the timeline for gaining Level 1 evidence for Prolaris.
Leadership And ManagementCEO Raha is acting with urgency, and focused on righting the ship.
Bears Say
Guidance And ExpectationsThe guidance cut for the year is significant and affects both GeneSight and Hereditary Cancer, making it difficult for investors to feel confident about the company's growth.
Market CompetitionIntensifying competitive pressures in NIPT and in hereditary cancer testing are limiting growth potential longer term.
Revenue OutlookThe implied 2H revenue outlook suggests a sales decline, well below the growth management has targeted.
Myriad Genetics News
MYGN FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $3.76 and its highest was $29.30 in the past 12 months.
What is Myriad Genetics’s market cap?
Myriad Genetics’s market cap is $356.73M.
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Nov 04, 2025 which is in 88 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on Aug 05, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.008 by $0.058.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Monthly dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is >-0.01.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 92,177,380 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.008. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Myriad Genetics?
Currently, no hedge funds are holding shares in MYGN
Myriad Genetics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.40 (65.37% Upside)
$6.40 (65.37% Upside)
Blogger Sentiment
Bullish
MYGN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 36.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.15%
12-Months-Change
Fundamentals
Return on Equity
-70.03%
Trailing 12-Months
Asset Growth
-37.58%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc. (MYGN) is a leading molecular diagnostic company that develops and markets genetic tests designed to assess an individual's risk of developing diseases, guide treatment decisions, and improve patient outcomes. Operating primarily in the healthcare sector, Myriad Genetics focuses on personalized medicine, particularly in oncology, women's health, and mental health. The company's core products include a range of genetic, genomic, and hereditary cancer tests, which are utilized by healthcare professionals to tailor medical treatment to individual patients.
MYGN Company Deck
MYGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted challenges with revenue decline and specific issues with GeneSight and hereditary cancer testing. However, some positive aspects included growth in prenatal testing and progress in the product pipeline. The company's guidance was revised downwards, indicating significant challenges ahead.View all MYGN earnings summariesMYGN Stock 12 Month Forecast
Average Price Target
$6.40
▲(65.37% Upside)
Technical Analysis
Ownership Overview
4.46% Insiders
23.92% Mutual Funds
0.40% Other Institutional Investors
45.59% Public Companies and
Individual Investors